Published in:
Open Access
01-12-2013 | Research article
Expression of TRAIL-splice variants in gastric carcinomas: identification of TRAIL-γ as a prognostic marker
Authors:
Andreas Krieg, Sabrina Mersch, Nadine Wolf, Nikolas H Stoecklein, Pablo E Verde, Jan Schulte am Esch 2nd, Sebastian Heikaus, Helmut E Gabbert, Wolfram T Knoefel, Csaba Mahotka
Published in:
BMC Cancer
|
Issue 1/2013
Login to get access
Abstract
Background
TNF-related apoptosis inducing ligand (TRAIL) belongs to the TNF-superfamily that induces apoptotic cell death in a wide range of neoplastic cells in vivo as well as in vitro. We identified two alternative TRAIL-splice variants, i.e. TRAIL-β and TRAIL-γ that are characterized by the loss of their proapoptotic properties. Herein, we investigated the expression and the prognostic values of the TRAIL-splice variants in gastric carcinomas.
Methods
Real time PCR for amplification of the TRAIL-splice variants was performed in tumour tissue specimens and corresponding normal tissues of 41 consecutive patients with gastric carcinoma. Differences on mRNA-expression levels of the TRAIL-isoforms were compared to histo-pathological variables and correlated with survival data.
Results
All three TRAIL-splice variants could be detected in both non-malignant and malignant tissues, irrespective of their histological staging, grading or tumour types. However, TRAIL-β exhibited a higher expression in normal gastric tissue. The proapoptotic TRAIL-α expression was increased in gastric carcinomas when compared to TRAIL-β and TRAIL-γ. In addition, overexpression of TRAIL-γ was associated with a significant higher survival rate.
Conclusions
This is the first study that investigated the expression of TRAIL-splice variants in gastric carcinoma tissue samples. Thus, we provide first data that indicate a prognostic value for TRAIL-γ overexpression in this tumour entity.